Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ticagrelor OD vs IR Tablets in Healthy Japanese Subjects
NCT02436577Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (6 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration at 48 hours and 1 more. Started Jun 2015; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02436577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436577.